Adial Pharmaceuticals has further adjourned its 2026 Annual Meeting of Stockholders with respect to Proposals 3, 4, 5, and 6 until October 26, 2026. The delay is intended to provide additional time to obtain Nasdaq's conditional approval of an Initial Listing Application related to those specific proposals.
Adial Pharmaceuticals has further adjourned its 2026 Annual Meeting of Stockholders with respect to Proposals 3, 4, 5, and 6 until October 15, 2026. The delay is intended to provide additional time to obtain Nasdaq's approval of an Initial Listing Application related to those specific proposals. Votes already cast on these proposals remain valid, and the record date remains August 17, 2026.
Adial Pharmaceuticals held its 2026 Annual Meeting of Stockholders on September 17, 2026, where shareholders elected two Class II directors and approved several equity-related proposals. Key approvals included an amendment to the 2017 Equity Incentive Plan, the adoption of the new 2026 Equity Incentive Plan, and the 2026 Employee Stock Purchase Plan.